| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000003719 |
| Receipt No. | R000004499 |
| Official scientific title of the study | A Phase II Study of Paclitaxel+S-1 for previously treated Non-Small Cell Lung Cancer |
| Date of disclosure of the study information | 2010/06/06 |
| Last modified on | 2016/07/31 (Ver. 11) |
| Basic information | ||
| Official scientific title of the study | A Phase II Study of Paclitaxel+S-1 for previously treated Non-Small Cell Lung Cancer | |
| Title of the study (Brief title) | A Phase II Study of Paclitaxel+S-1 for previously treated Non-Small Cell Lung Cancer | |
| Region |
|
|
| Condition | ||
| Condition | Advanced or relapsed Non-Small Cell Lung Cancer | |
| Classification by specialty |
|
|
| Classification by malignancy | Malignancy | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To investigate efficacy and safety of Paclitaxel+S- for previously treated Non-Small Cell Lung Cancer |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Exploratory |
| Trial characteristics_2 | Pragmatic |
| Developmental phase | Phase II |
| Assessment | |
| Primary outcomes | Response rate |
| Key secondary outcomes | Progression free survival
1-year suvival rate safety |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Paclitaxel + S-1 | |
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1)Histologically confirmed Non-Small Cell Lung Cancer
2)Advanced Stage (IV or IIIB) 3)With measurable lesion 4)One more prior platinum-based chemotherapy 5)The case of prior Paclitaxel or S-1 treatment is accceptable. 6)20<=, <75 years 7)Performance Status(ECOG):0-1 8)Oral intake is possible 9)Adequate organ functions 10)Patients who have estimated life expectancy longer than 3 months 11)Written informed consent |
|||
| Key exclusion criteria | 1)uncontrollablenangina pectoris, arrythmia or heart failure
2)Hystory of active double cancer 3)complication of superior vena cava syndrome 4)complication ofliver cirrhosis 5)Interstitial pneumonaitis on chest x-ray 6)complication ofgastrointestinal bleeding 7)poorly controled diabetes mellitus 8)symptoms of ileus or watery diarrhea 9)Patients with serious infections or susupected infections with fever 10)complication of massive pericardial effusion, ascites or pleural sffusion 11)Pregnant or lactating woman 12)Symptomatic brain metastasis 13)Patients whose participation in the trial is judged to be inappropriate by the attending doctor. |
|||
| Target sample size | 50 | |||
| Research contact person | |
| Name of lead principal investigator | Fumio Imamura |
| Organization | Osaka Medical Center for Cancer and Cardiovascular Diseases |
| Division name | Pulmonary Oncology |
| Address | 1-3-3 Nakamichi Higashinari-ku, Osaka 537-8511 |
| TEL | 06-6971-1181 |
| imamura-fu@mc.pref.osaka.jp | |
| Public contact | |
| Name of contact person | Kazumi Nishino |
| Organization | Osaka Medical Center for Cancer and Cardiovascular Diseases |
| Division name | Pulmonary Oncology |
| Address | 1-3-3 Nakamichi Higashinari-ku, Osaka 537-8511 |
| TEL | 06-6972-1181 |
| Homepage URL | |
| nisino-ka@mc.pref.osaka.jp | |
| Sponsor | |
| Institute | Osaka Medical Center for Cancer and Cardiovascular Diseases |
| Institute | |
| Department | |
| Funding Source | |
| Organization | none |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | Japan |
| Other related organizations | |
| Co-sponsor | Osaka University Hospital Department of lung diseases |
| Name of secondary funder(s) | none |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 大阪大学医学部附属病院(大阪府)大阪府急性期総合医療センター(大阪府)国立病院機構刀根山病院(大阪府)国立病院機構大阪南医療センター(大阪府)公立学校共済組合近畿中央病院(兵庫県) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete |
|
||||||
| Date analysis concluded |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000004499 |